BTIG Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $16
Portfolio Pulse from richadhand@benzinga.com
BTIG analyst Justin Zelin has initiated coverage on ProKidney (NASDAQ:PROK) with a Buy rating and a price target of $16.
July 25, 2023 | 8:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ProKidney's stock may see positive movement following BTIG's initiation of coverage with a Buy rating and a price target of $16.
Analyst ratings often influence stock prices. In this case, BTIG's Buy rating and price target of $16 for ProKidney could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100